Weak correlation between total psoas muscle area and sarcopenia index for children with brain tumor.
brain neoplasms
children
muscle mass
pediatrics
psoas muscles
sarcopenia
Journal
Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition
ISSN: 1941-2452
Titre abrégé: Nutr Clin Pract
Pays: United States
ID NLM: 8606733
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
revised:
04
03
2023
received:
28
09
2022
accepted:
19
03
2023
medline:
13
7
2023
pubmed:
23
4
2023
entrez:
23
04
2023
Statut:
ppublish
Résumé
The aim of this study is to determine whether the sarcopenia index (SI) is a viable measure of muscle mass in pediatric patients with brain tumors. Retrospectively enrolled patients (1-16 years) who had serum creatinine (Cr) and cystatin C (CysC) levels evaluated within 28 days of an abdomen magnetic resonance imaging scan for the lumbar vertebrae 3-4 total psoas muscle area (tPMA) were studied. Variables were compared using their z scores calculated from age- and sex-dependent reference. We hypothesized that a low SI indicated less skeletal muscle, and therefore potentially indicated sarcopenia. The SI z score had no correlation with tPMA z score (r = 0.004). Both Cr and CysC levels were positively correlated with tPMA in z scores (r = 0.249 and 0.320). tPMA strongly correlated with body mass index in z scores (r = 0.582). The z scores of tPMA, Cr and CysC decreased with elevated World Health Organization grades of tumor, but the z scores of SI showed no significant dependence on WHO grades. The correlation of SI to muscle mass is very weak in our sample of pediatric patients with brain tumor. Its viability as biomarker for sarcopenia needs more study.
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
838-849Informations de copyright
© 2023 American Society for Parenteral and Enteral Nutrition.
Références
Azzolino D, Alkahtani S, Cesari M. Definitions of sarcopenia across the world. In: Veronese N, Beaudart C, Sabico S, eds. Sarcopenia: Research and Clinical Implications. Practical Issues in Geriatrics. Springer; 2021:17-26.
Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis. Age Ageing. 2010;39(4):412-423.
Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31.
Erratum in: Age Ageing. 2019;48(4):601.
Vaishya R, Gupta BM, Misra A, Mamdapurj GM, Vaish A. Global research in sarcopenia: high-cited papers, research institutions, funding agencies and collaborations, 1993-2022. Diabetes Metab Syndr. 2022;16(11):102654.
Ooi PH, Thompson-Hodgetts S, Pritchard-Wiart L, Gilmour SM, Mager DR. Pediatric sarcopenia: A paradigm in the overall definition of malnutrition in children. JPEN J Parenter Enteral Nutr. 2020;44(3):407-418.
Metzger GA, Carsel A, Sebastião YV, Deans KJ, Minneci PC. Does sarcopenia affect outcomes in pediatric surgical patients? A scoping review. J Pediatr Surg. 2021;56(11):2099-2106.
McCarthy HD, Cole TJ, Fry T, Jebb SA, Prentice AM. Body fat reference curves for children. Int J Obes. 2006;30(4):598-602.
McCarthy HD, Samani-Radia D, Jebb SA, Prentice AM. Skeletal muscle mass reference curves for children and adolescents. Pediatr Obes. 2014;9(4):249-259.
Kim K, Hong S, Kim EY. Reference values of skeletal muscle mass for Korean children and adolescents using data from the Korean National Health and Nutrition Examination Survey 2009-2011. PLoS One. 2016;11(4):e0153383.
Webber CE, Barr RD. Age- and gender-dependent values of skeletal muscle mass in healthy children and adolescents. J Cachexia Sarcopenia Muscle. 2012;3(1):25-29.
Schmidt SC, Bosy-Westphal A, Niessner C, Woll A. Representative body composition percentiles from bioelectrical impedance analyses among children and adolescents. The MoMo study. Clin Nutr. 2019;38(6):2712-2720.
Guo B, Wu Q, Gong J, et al. Relationships between the lean mass index and bone mass and reference values of muscular status in healthy Chinese children and adolescents. J Bone Miner Metab. 2016;34(6):703-713.
Been E, Shefi S, Kalichman L, Bailey JF, Soudack M. Cross-sectional area of lumbar spinal muscles and vertebral endplates: a secondary analysis of 91 computed tomography images of children aged 2-20. J Anat. 2018;233(3):358-369.
Lurz E, Patel H, Lebovic G, et al. Paediatric reference values for total psoas muscle area. J Cachexia Sarcopenia Muscle. 2020;11(2):405-414.
Dodds RM, Syddall HE, Cooper R, et al. Grip Strength across the life course: normative data from twelve british studies. PLoS One. 2014;9(12):e113637.
Dodds RM, Syddall HE, Cooper R, Kuh D, Cooper C, Sayer AA. Global variation in grip strength: a systematic review and meta-analysis of normative data. Age Ageing. 2016;45(2):209-216.
Sumnik Z, Matyskova J, Hlavka Z, Durdilova L, Soucek O, Zemkova D. Reference data for jumping mechanography in healthy children and adolescents aged 6-18 years. J Musculoskelet Neuronal Interact. 2013;13(3):297-311.
Lurz E, Patel H, Frimpong RG, et al. Sarcopenia in children with end-stage liver disease. J Pediatr Gastroenterol Nutr. 2018;66(2):222-226.
Mangus RS, Bush WJ, Miller C, Kubal CA. Severe sarcopenia and increased fat stores in pediatric patients with liver, kidney, or intestine failure. J Pediatr Gastroenterol Nutr. 2017;65(5):579-583.
Davies A, Nixon A, Muhammed R, et al. Reduced skeletal muscle protein balance in paediatric Crohn's disease. Clin Nutr. 2020;39(4):1250-1257.
Doulgeraki AE, Athanasopoulou HI, Katsalouli MS, Petrocheilou GM, Paspati IN, Monopolis IK. Body composition of patients with Duchenne muscular dystrophy: the Greek experience. Acta Neurol Belg. 2016;116(4):565-572.
Mueske NM, Mittelman SD, Wren TAL, Gilsanz V, Orgel E. Myosteatosis in adolescents and young adults treated for acute lymphoblastic leukemia. Leuk Lymphoma. 2019;60(13):3146-3153.
Mager DR, Hager A, Ooi PH, Siminoski K, Gilmour SM, Yap JYK. Persistence of sarcopenia after pediatric liver transplantation is associated with poorer growth and recurrent hospital admissions. JPEN J Parenter Enteral Nutr. 2019;43(2):271-280.
Rayar M, Webber CE, Nayiager T, Sala A, Barr RD. Sarcopenia in children with acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2013;35(2):98-102.
Steffl M, Chrudimsky J, Tufano JJ. Using relative handgrip strength to identify children at risk of sarcopenic obesity. PLoS One. 2017;12(5):e0177006.
Woolfson JP, Perez M, Chavhan GB, et al. Sarcopenia in children with end-stage liver disease on the transplant waiting list. Liver Transpl. 2021;27(5):641-651.
Maratova K, Soucek O, Matyskova J, et al. Muscle functions and bone strength are impaired in adolescents with type 1 diabetes. Bone. 2018;106:22-27.
Anjanappa M, Corden M, Green A, et al. Sarcopenia in cancer: risking more than muscle loss. Tech Innov Patient Support Radiat Oncol. 2020;16:50-57.
Triarico S, Rinninella E, Mele MC, Cintoni M, Attinà G, Ruggiero A. Prognostic impact of sarcopenia in children with cancer: a focus on the psoas muscle area (PMA) imaging in the clinical practice. Eur J Clin Nutr. 2022;76(6):783-788.
Joffe L, Schadler KL, Shen W, Ladas EJ. Body composition in pediatric solid tumors: state of the science and future directions. J Natl Cancer Inst Monogr. 2019;2019(54):144-148.
Suzuki D, Kobayashi R, Sano H, Hori D, Kobayashi K. Sarcopenia after induction therapy in childhood acute lymphoblastic leukemia: its clinical significance. Int J Hematol. 2018;107(4):486-489.
Murphy AJ, White M, Davies PS. Body composition of children with cancer. Am J Clin Nutr. 2010;92(1):55-60.
Murphy AJ, White M, Elliott SA, Lockwood L, Hallahan A, Davies PS. Body composition of children with cancer during treatment and in survivorship. Am J Clin Nutr. 2015;102(4):891-896.
Daly LE, Power DG, O'Reilly Á, et al. The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma. Br J Cancer. 2017;116(3):310-317.
Prado CMM, Baracos VE, McCargar LJ, et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res. 2007;13(11):3264-3268.
Prado CMM, Baracos VE, McCargar LJ, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res. 2009;15(8):2920-2926.
Shachar SS, Deal AM, Weinberg M, et al. Skeletal muscle measures as predictors of toxicity, hospitalization, and survival in patients with metastatic breast cancer receiving taxane-based chemotherapy. Clin Cancer Res. 2017;23(3):658-665.
Kawakubo N, Kinoshita Y, Souzaki R, et al. The influence of sarcopenia on high-risk neuroblastoma. J Surg Res. 2019;236:101-105.
Shachar SS, Williams GR, Muss HB, Nishijima TF. Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review. Eur J Cancer. 2016;57:58-67.
Brantlov S, Jødal L, Lange A, Rittig S, Ward LC. Standardisation of bioelectrical impedance analysis for the estimation of body composition in healthy paediatric populations: a systematic review. J Med Eng Technol. 2017;41(6):460-479.
Gonzalez MC. Using bioelectrical impedance analysis for body composition assessment: sorting out some misunderstandings. JPEN J Parenter Enteral Nutr. 2019;43(8):954-955.
Sun J, Yang H, Cai W, et al. Serum creatinine/cystatin C ratio as a surrogate marker for sarcopenia in patients with gastric cancer. BMC Gastroenterol. 2022;22(1):26.
Osaka T, Hamaguchi M, Hashimoto Y, et al. Decreased the creatinine to cystatin C ratio is a surrogate marker of sarcopenia in patients with type 2 diabetes. Diabetes Res Clin Pract. 2018;139:52-58.
Kusunoki H, Tsuji S, Wada Y, et al. Relationship between sarcopenia and the serum creatinine/cystatin C ratio in Japanese rural community-dwelling older adults. JCSM Clin Rep. 2018;3(1):e00053.
Hirai K, Tanaka A, Homma T, et al. Serum creatinine/cystatin C ratio as a surrogate marker for sarcopenia in patients with chronic obstructive pulmonary disease. Clin Nutr. 2021;40(3):1274-1280.
Fu X, Tian Z, Wen S, et al. A new index based on serum creatinine and cystatin C is useful for assessing sarcopenia in patients with advanced cancer. Nutrition. 2021;82:111032.
Kashani K, Sarvottam K, Pereira NL, Barreto EF, Kennedy CC. The sarcopenia index: a novel measure of muscle mass in lung transplant candidates. Clin Transplant. 2018;32(3):e13182.
Lopez-Ruiz A, Kashani K. Assessment of muscle mass in critically ill patients: role of the sarcopenia index and images studies. Curr Opin Clin Nutr Metab Care. 2020;23(5):302-311.
Lin Y-L, Chen S-Y, Lai Y-H, et al. Serum creatinine to cystatin C ratio predicts skeletal muscle mass and strength in patients with non-dialysis chronic kidney disease. Clin Nutr. 2020;39(8):2435-2441.
Barreto EF, Poyant JO, Coville HH, et al. Validation of the sarcopenia index to assess muscle mass in the critically ill: a novel application of kidney function markers. Clin Nutr. 2019;38(3):1362-1367.
Tabara Y, Kohara K, Okada Y, Ohyagi Y, Igase M. Creatinine-to-cystatin C ratio as a marker of skeletal muscle mass in older adults: J-SHIPP study. Clin Nutr. 2020;39(6):1857-1862.
Yang Q, Zhang M, Sun P, et al. Cre/CysC ratio may predict muscle composition and is associated with glucose disposal ability and macrovascular disease in patients with type 2 diabetes. BMJ Open Diabetes Res Care. 2021;9(2):e002430.
Romeo FJ, Chiabrando JG, Seropian IM, et al. Sarcopenia index as a predictor of clinical outcomes in older patients undergoing transcatheter aortic valve replacement. Catheter Cardiovasc Interv. 2021;98(6):E889-E896.
He Q, Jiang J, Xie L, Zhang L, Yang M. A sarcopenia index based on serum creatinine and cystatin C cannot accurately detect either low muscle mass or sarcopenia in urban community-dwelling older people. Sci Rep. 2018;8(1):11534.
Singhal S, Singh S, Upadhyay AD, et al. Serum creatinine and cystatin C-based index can be a screening biomarker for sarcopenia in older population. Eur Geriatr Med. 2019;10(4):625-630.
Chou JH, Roumiantsev S, Singh R. PediTools electronic growth chart calculators: applications in clinical care, research, and quality improvement. J Med Internet Res. 2020;22(1):e16204.
Centers for Disease Control and Prevention, National Center for Health Statistics. Growth Charts-Percentile data files with LMS values. Updated September 9, 2010. Accessed March 2, 2023. https://www.cdc.gov/growthcharts/who_charts.htm
Shengjuan Y. Nutritional Risk Screening and High Risk Factors for Malnutrition in Pediatric Inpatients. Dissertation. Chongqing Medical University; 2013. Accessed March 2, 2023. https://kns.cnki.net/KCMS/detail/detail.aspx?dbname=CMFD201401&filename=1014108939.nh
Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23(8):1231-1251.
Applied Health Research Centre. Pediatric total psoas muscle area (tPMA) z-score calculator. Accessed March 2, 2023. https://ahrc-apps.shinyapps.io/sarcopenia/
Liu C, Wen J, Xiang J, et al. Age- and sex-specific reference intervals for the serum cystatin C/creatinine ratio in healthy children (0-18 years old). J Int Med Res. 2019;47(7):3151-3159.
Kashani KB, Frazee EN, Kukrálová L, et al. Evaluating muscle mass by using markers of kidney function: development of the sarcopenia index. Crit Care Med. 2017;45(1):e23-e29.
Ness KK, Krull KR, Jones KE, et al. Physiologic frailty as a sign of accelerated aging among adult survivors of childhood cancer: a report from the St Jude Lifetime Cohort study. J Clin Oncol. 2013;31(36):4496-4503.
Chemaitilly W, Li Z, Huang S, et al. Anterior hypopituitarism in adult survivors of childhood cancers treated with cranial radiotherapy: a report from the St Jude Lifetime Cohort study. J Clin Oncol. 2015;33(5):492-500.
Talvensaari KK, Jämsen A, Vanharanta H, Lanning M. Decreased isokinetic trunk muscle strength and performance in long-term survivors of childhood malignancies: correlation with hormonal defects. Arch Phys Med Rehabil. 1995;76(11):983-988.
Meacham LR, Gurney JG, Mertens AC, et al. Body mass index in long-term adult survivors of childhood cancer. Cancer. 2005;103(8):1730-1739.
Ritz A, Froeba-Pohl A, Kolorz J, et al. Total Psoas muscle area as a marker for sarcopenia is related to outcome in children with neuroblastoma. Front Surg. 2021;8:718184.
Ritz A, Kolorz J, Hubertus J, et al. Sarcopenia is a prognostic outcome marker in children with high-risk hepatoblastoma. Pediatr Blood Cancer. 2021;68(5):e28862.
Vinge E, Lindergård B, Nilsson-Ehle P, Grubb A. Relationships among serum cystatin C, serum creatinine, lean tissue mass and glomerular filtration rate in healthy adults. Scand J Clin Lab Invest. 1999;59(8):587-592.
Viollet L, Gailey S, Thornton DJ, et al. Utility of cystatin C to monitor renal function in duchenne muscular dystrophy. Muscle Nerve. 2009;40(3):438-442.
Macdonald J, Marcora S, Jibani M, et al. GFR estimation using cystatin C is not independent of body composition. Am J Kidney Dis. 2006;48(5):712-719.
Séronie-Vivien S, Delanaye P, Piéroni L, Mariat C, Froissart M, Cristol JP. Cystatin C: current position and future prospects. Clin Chem Lab Med. 2008;46(12):1664-1686.
Marmarinos A, Garoufi A, Panagoulia A, et al. Cystatin-C levels in healthy children and adolescents: influence of age, gender, body mass index and blood pressure. Clin Biochem. 2016;49(1):150-153.
Retnakaran R, Connelly PW, Harris SB, Zinman B, Hanley AJG. Cystatin C is associated with cardiovascular risk factors and metabolic syndrome in Aboriginal youth. Pediatr Nephrol. 2007;22(7):1007-1013.
Muntner P, Winston J, Uribarri J, Mann D, Fox CS. Overweight, obesity, and elevated serum cystatin C levels in adults in the United States. Am J Med. 2008;121(4):341-348.
Leto G, Crescimanno M, Flandina C. On the role of cystatin C in cancer progression. Life Sci. 2018;202:152-160.
Lien YHH. Looking for sarcopenia biomarkers. Am J Med. 2017;130(5):502-503.